计算溶液所需的质量、体积或浓度。
为什么选择此级别
，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein ( RSV F ) protein inhibitor. Ziresovir shows anti-RSV activity ( EC 50 =3 nM) and highlights pharmacokinetics in animal species
In Vitro
Ziresovir shows different efficacy in Wild Type (WT) and Mutant Strains RSV with EC 50 /EC 90 values (μM) of 0.003/0.005 (WT), 2.1/10.0 (D486N), and >10/>10 (D489A), respectively. RO-0529 (100 nM; 4 d) inhibits RSV F protein-induced cell–cell fusion process, and suppresses the syncytia formation induced by the RSV F protein. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Ziresovir (12.5 mg/kg, 50 mg/kg; p.o.; twice daily; 4 d) results reduction of RSV titer in mouse lung . Ziresovir (10 mg/kg; p.o.; single dose) exhibits good oral exposure and bioavailability with F(%) of 32% in male Wistar-Han rats . Ziresovir (150 mg/kg; p.o.; single dose) demonstrates a high tissue distribution to lung than plasma in CD-1 Mice . Pharmacokinetics of Ziresovir in male Wistar-Han rats Dose (mg/kg) AUC 0-24h (p.o.) (ng·h/mL) CL (mL/min/kg) T 1/2 (i.v.) (h) V ss (L/kg) F (%) 2 mg/kg (iv) or 10 mg/kg (po) 906 58 1.2 3.9 32 Pharmacokinetics of Ziresovir in CD-1 Mice Dose (mg/kg) AUC 0-24h (p.o.) (μg·h/L) tissue/lasma AUC 0-24h ratio (μg·h/L) T 1/2 (h) T max (h) C max (μg/L) plasma 8,380 1 1.02 0.25 5090 lung 72,400 8.6 3.31 1 22700 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/c mice infected by RSV Dosage: 12.5 mg/kg, 50 mg/kg Administration: Oral gavage; twice daily; 4 days Result: Resulted >1 log unit of viral titer reduction in the lung of infected mice at the dose level as low as 12.5 mg/kg. Reduced viral titer to 1.9 log units compared to vehicle at 50 mg/kg dose.
IC50& Target:RSV F protein (respiratory syncytial virus fusion protein), EC50: 3 nM (RSV F)
规格
别名
齐瑞索韦
规格或纯度
10mM in DMSO
英文名称
Ziresovir
生化机理
Ziresovir（AK0529;RO-0529）是一种强效、选择性和口服生物可用的呼吸道合胞病毒（RSV）融合（F）蛋白（RSV F）抑制剂。Ziresovir 具有抗 RSV 活性（EC 50 =3 nM），在动物体内的药代动力学表现突出
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
作用机制
融合糖蛋白 F0 抑制剂
名称和识别符
分子类型
小分子
Isomeric SMILES
CC1=CC2=C(C=C1)N=C(N=C2NCC3(COC3)N)N4CCS(=O)(=O)C5=CC=CC=C5C4
关联CAS
PubChem CID
MeSH Entry Terms
AK-0529;AK0529;N-((3-aminooxetan-3-yl)methyl)-2-(1,1-dioxo-3,5-dihydro-2H-1lambda6,4-benzothiazepin-4-yl)-6-methylquinazolin-4-amine;RO-0529;RO0529;ziresovir
分子量
439.53
技术文档
高级数据
产品属性
| ALogP | 1.8 |
|---|
安全和危险性（GHS）
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）